Replies to post #298533 on Anavex Life Sciences Corp (AVXL)

[boi568]

Understood, but AD and Rett SAS legal eligibility are directly comparable. I believe that Missling is taking the same corporate policy in AD as he just announced in Rett.

There are business reasons here for the decision (such as the pricing complexities) but also significant business costs (revenue and goodwill). Hard to believe he would do different things in such similar circumstances.

[Investor2014]

Try to read this for what it says, rather than what would be nicer it said.

Ram Selvaraju -- H.C. Wainwright -- Analyst

It's very helpful there. Also, I was wondering if you could comment on the current status of the special access team in Australia and whether you think that that element of the overall Rett syndrome program, is likely to yield usable or significant clinical data that you could use in support of future regulatory applications? And if you could maybe give us a sense of what the size of that program is right now? You know, how many patients are receiving drug as part of the (Inaudible)?

Christopher Missling -- President and Chief Executive Officer

Yeah. So the compassionate use program in Australia has the benefit that it allows for patients who are on the clinical study, and after finishing the study on the extension study, and after finishing the clinical extension study would basically be left up without any further treatment. And that allows them to continue the drug with the supervision of a physician and right now, we limit this pretty much to the existing patients which entered our study. And the advantage is that once the drug will get approved, they will be overly automatically becoming eligible then to be prescribed the drug once it's approved for market authorization.